Analysts show less optimism post-results due to lowered revenue forecasts and minor EPS downgrade. Despite growth acceleration, China Resources Double-Crane PharmaceuticalLtd is predicted to lag behind industry average. Concerns arise as EPS estimates are reduced, indicating potential business challenges.

Despite strong earnings growth, the company's P/E ratio aligns with others, hinting at overlooked limited growth rates. If P/E aligns with recent growth rates, investors may face disappointment. The company's medium-term growth is lower than market forecast, risking a share price decline.

Despite declining earnings per share, market sentiment for Zhejiang Medicine remains steady. The company's disappointing performance over the past year and five years suggests potential long-term share price weakness.

Despite a recent boost in China Resources Double-Crane Pharmaceutical's stock, its low P/E ratio suggests investors expect limited future growth. The company's forecast growth is lower than the wider market, indicating a potential lack of strong share price rise in the near future.

Zhejiang Hisun Pharmaceutical's low P/E ratio may be due to market expectations of declining earnings. The weak earnings outlook could be causing the low share price, making it hard for the price to rise significantly soon.

Despite expected EPS rise, Zhejiang Medicine's P/E ratio stays below market, indicating shareholder skepticism. Future earnings could be volatile with potential unseen threats preventing P/E ratio from reflecting positive outlook.

Despite strong recent performance, the company's typical P/E ratio and limited growth rates may make maintaining prices difficult. Weak earnings and slower market growth suggest a potential share price decline, possibly lowering the P/E.

Investors' belief that Zhuhai Rundu Pharmaceutical will underperform the broader market may explain its low P/E ratio. If recent medium-term earnings trends persist, the share price is unlikely to see significant movement soon.

The company's five-year earnings growth track record has boosted its market reputation. Despite modest recent returns, the five-year total shareholder return is impressive at 13% per year. The stock's peak may have passed, or the price may be stabilizing as the business continues to perform.